Cohance Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve the Audited Financial ....
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences Ltd (formerly Suven Pharmaceuticals Limited) has scheduled a Board Meeting on May 12, 2026 to consider and approve the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The company has also reminded that the Trading Window for Designated Persons and their relatives remains closed until May 14, 2026, in line with SEBI regulations. This is a standard regulatory intimation under SEBI LODR Regulation 29. No specific financial details or preliminary numbers have been disclosed in this notice.
This is a routine pre-result announcement notice. The actual financial results and any significant deviations will be known only after the board meeting on May 12, 2026. Investors should await the official results disclosure for any material signals on company performance.